Unfortunately, one can observe that, from
approximately 20 traditional pharmaceutical companies investing in antibiotic
research in the 1980s, there are now only five with significant active
internal research programs. As a result, most novel antibiotic development is
now being conducted by small biotech companies.
For many analysts , the increasing need for inventory level management and the movement of goods in real time to minimize the lack-of-stock situations are the major reasons for the growth of the market. Increased product availability and reduced inventory costs are also driving the market growth, according to Technavio Research.
Comments
Post a Comment